Hemoglobinopathies: Clinical Trials

55 trials for Hemoglobinopathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

55 terminated. 55 Phase 2, 13 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 255Terminated 55
Phase 113Terminated 13
Phase 31Terminated 1

Follow Hemoglobinopathies: new trials by email Literature Review of Hemoglobinopathies trials Research Report on Hemoglobinopathies

Trials (filtered) newest first · largest first

All 55 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open-Label Extension Study to Pioneer Study 6058-SCD-101
Pociredir - Sickle Cell Disease
Phase 2TerminatedFulcrum Therapeutics12026-03-302026-10-28
Siplizumab for Sickle Cell Disease Transplant
Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell
Phase 1 / Phase 2TerminatedColumbia University12023-09-282026-06-10
Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease
ALXN1820 - Sickle Cell Disease (SCD)
Phase 2TerminatedAlexion Pharmaceuticals, Inc.22023-02-222025-01-13
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
Osivelotor - Sickle Cell Disease
Phase 2 / Phase 3TerminatedPfizer472023-01-052026-03-19
AB1 in Adult Patients With Sickle Cell Disease (SCD)
AB1 - Sickle Cell Disease
Phase 1 / Phase 2TerminatedNirmish Shah162022-12-052026-10-15
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
MGTA-145, Plerixafor - Sickle Cell Disease
Phase 2TerminatedEnsoma12022-06-242025-07-25
A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
Voxelotor - Sickle Cell Disease, Sickle Cell Nephropathy
Phase 1 / Phase 2TerminatedUniversity of Illinois at Chicago122021-03-162025-04-03
Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)
sapablursen - Beta Thalassemia Intermedia
Phase 2TerminatedIonis Pharmaceuticals, Inc.292020-09-242025-02-18
A Study of IMR-687 in Subjects With Sickle Cell Disease
IMR-687, Placebo - Sickle Cell Disease
Phase 2TerminatedCardurion Pharmaceuticals, Inc.1152020-08-132025-05-15
Imatinib for Pain in Sickle Cell Anemia
Imatinib Mesylate - Sickle Cell Disease
Phase 1 / Phase 2TerminatedIndiana University72020-02-262026-01-29
Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD
Voxelotor - Sickle Cell Disease
Phase 2TerminatedPfizer62020-01-092023-11-21
Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere
Hydroxyurea, Hydroxyurea Oral Capsule - Sickle Cell Disease, Thalassemia
Phase 2TerminatedSt. Jude Children's Research Hospital12019-06-102022-03-18
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases
Blood and Marrow Transplant - Sickle Cell Disease, Thalassemia
Phase 2TerminatedMasonic Cancer Center, University of Minnesota52018-07-022024-07-12
Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers
Topical Sodium Nitrite, Placebo - Sickle Cell Disease
Phase 2Terminatedcaterina P minniti182018-04-062025-05-07
Omega-3 Fatty Acids in Sickle Cell Disease
SCD-Omegatex™ - Sickle Cell Disease
Phase 1 / Phase 2TerminatedRobin E. Miller42018-01-252020-10-19
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission
Phase 2TerminatedRoswell Park Cancer Institute312017-12-072025-07-04
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
LJPC-401 - Beta-Thalassemia
Phase 2TerminatedLa Jolla Pharmaceutical Company842017-11-302021-07-29
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Rimiducid, rivogenlecleucel - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Phase 1 / Phase 2TerminatedBellicum Pharmaceuticals1872017-01-012023-09-26
Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease
Voxelotor - Sickle Cell Disease
Phase 2TerminatedPfizer1472016-07-052025-08-15
Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies
CordIn - Sickle Cell Disease, Thalassemia
Phase 1 / Phase 2TerminatedGamida Cell ltd12016-04-042019-06-26

Showing 20 of 55. Sign in to see all of them.

Narrower conditions

Anemia, Sickle Cell (46)  ·  Thalassemia (12)  ·  beta-Thalassemia (8)  ·  Hemoglobin SC Disease (5)  ·  Hypertension, Pulmonary (5)  ·  Anemia, Diamond-Blackfan (4)  ·  Leukemia, Myeloid, Acute (4)  ·  Myelodysplastic Syndromes (4)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)  ·  Vaso-Occlusive Crises (4)  ·  Anemia (3)  ·  Anemia, Aplastic (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Acute Chest Syndrome (2)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (55)  ·  Hemic and Lymphatic Diseases (55)  ·  Anemia, Hemolytic, Congenital (54)  ·  Genetic Diseases, Inborn (54)  ·  Hematologic Diseases (54)  ·  Anemia, Hemolytic (53)  ·  Anemia (51)  ·  Cardiovascular Diseases (7)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Respiratory Tract Diseases (7)  ·  Vascular Diseases (7)  ·  Lung Diseases (6)  ·  Thalassemia (6)  ·  Bone Marrow Diseases (5)

Interventions

Cyclophosphamide (7)  ·  Hydroxyurea (5)  ·  Whole-Body Irradiation (4)  ·  fludarabine phosphate (4)  ·  Busulfan (3)  ·  Sirolimus (3)  ·  Tacrolimus (3)  ·  fludarabine (3)  ·  voxelotor (3)  ·  AP 1903 reagent (2)  ·  Alemtuzumab (2)  ·  Glutamine (2)  ·  Mycophenolic Acid (2)  ·  Pyrrolidonecarboxylic Acid (2)  ·  Rituximab (2)

Sponsors

Baylor College of Medicine (5)  ·  Pfizer (3)  ·  St. Jude Children's Research Hospital (3)  ·  Bellicum Pharmaceuticals (2)  ·  Children's Hospital Los Angeles (2)  ·  University of North Carolina, Chapel Hill (2)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Ann & Robert H Lurie Children's Hospital of Chicago (1)  ·  Anthera Pharmaceuticals (1)  ·  Baxalta now part of Shire (1)  ·  Boston Children's Hospital (1)  ·  Boston University (1)  ·  Cardurion Pharmaceuticals, Inc. (1)  ·  Carelon Research (1)  ·  Celgene (1)

Countries

United States (48)  ·  United Kingdom (8)  ·  Italy (6)  ·  Lebanon (6)  ·  Greece (4)  ·  Turkey (Türkiye) (3)  ·  Australia (2)  ·  Canada (2)  ·  France (2)  ·  Thailand (2)  ·  Egypt (1)  ·  Ghana (1)  ·  Jamaica (1)  ·  Kenya (1)  ·  Morocco (1)

Top investigators

Kenneth I Ataga, MD (2)  ·  Vivien Sheehan, MD (2)  ·  Allistair Abraham, MD (1)  ·  Andrew Gilman, MD (1)  ·  Brigitta Mueller, MD (1)  ·  Caterina Minniti, M.D. (1)  ·  Catherine J. Wu, MD (1)  ·  Christen L Ebens, MD, MPH (1)  ·  Craig D Seaman, MD (1)  ·  Damiano Rondelli, MD (1)  ·  Debra Weiner, MD, PhD (1)

Results publications

PMID 14550808, PMID 21275961, PMID 21527519, PMID 21900080, PMID 22983573, PMID 23973010, PMID 24677033, PMID 24988120, PMID 25459642, PMID 29296761, PMID 30878319, PMID 31322833, PMID 34014839, PMID 34990411, PMID 35451176, PMID 37254256, PMID 37439373, PMID 37975597, PMID 39428602, PMID 40419809, PMID 41569644, PMID 42224366, PMID 42241700

NIH funding

2019 (2), K23HL127100 (1), P01CA015396 (1), P20GM109021 (1), P30CA006973 (1), R01HL094592 (1), U01HL065232 (1), U01HL065238 (1), U01HL065239 (1), U01HL065244 (1), U01HL065260 (1), U54HL070587 (1)